ArdorComm Media Group

Monday, November 16, 2026 11:06 PM

Merck

More Than 16,000 Ebola Vaccine Doses Arrive in Outbreak-Hit DRC

More than 16,000 doses of the Ervebo Ebola vaccine arrived in the Democratic Republic of Congo (DRC) on Friday, August 21, as the country battles its deadliest Ebola outbreak, according to an AFP journalist at the scene. A total of 16,250 doses were delivered by plane to Kinshasa, forming part of the 70,000 Ervebo doses made available to the DRC by the World Health Organisation (WHO). Of the total allocation, 20,000 doses are earmarked for a clinical trial, while 50,000 will be administered to frontline and healthcare workers. The DRC declared its 17th Ebola outbreak on May 15, although health officials believe the virus had been circulating for several weeks before the announcement. The outbreak has affected areas in the country’s north and east, where limited state presence, weak healthcare infrastructure and the presence of armed groups have complicated the response. According to the latest figures from Congolese authorities, the outbreak has resulted in 5,290 confirmed cases and 2,516 deaths. Julien Harneis, the UN’s senior Ebola coordinator, warned on Friday that the outbreak was “growing exponentially”. The Ervebo vaccine, developed by pharmaceutical company Merck, is approved for protection against the Zaire strain of Ebola but has not been approved for the Bundibugyo strain currently circulating in the DRC. WHO experts are yet to establish whether it can protect humans against the strain, although preliminary evidence, including animal studies, indicates that it may provide some level of protection. DRC Health Minister Samuel Roger Kamba said Ervebo had already been deployed during previous outbreaks, including extensively during the 2018-2020 Ebola epidemic. WHO vaccine experts this month recommended conducting a large-scale human trial to determine whether Ervebo can provide cross-protection against the Bundibugyo strain. The trial is expected to provide crucial evidence as authorities seek to contain the rapidly expanding outbreak. Researchers are also working on vaccines specifically designed to target the Bundibugyo strain. Moderna is developing an mRNA-based candidate, while another vaccine is being developed by the University of Oxford. Singapore-based Hilleman Laboratories is also set to develop an “rVSV Bundibugyo” vaccine, which WHO has described as the most promising candidate. Ebola spreads primarily through contact with infected bodily fluids and can cause severe fever and other serious symptoms. The virus has killed more than 15,000 people across Africa over the past five decades. Source: AFP  

More Than 16,000 Ebola Vaccine Doses Arrive in Outbreak-Hit DRC Read More »

FDA Approves First-Ever Cholesterol-Lowering Pill Targeting PCSK9 for High-Risk Patients

The U.S. Food and Drug Administration (FDA) has approved Lipfendra, a groundbreaking oral medication developed by Merck, marking the first pill designed to lower cholesterol by targeting the PCSK9 protein. Until now, this treatment approach was available only through injectable medicines. The newly approved drug is intended for patients whose LDL (“bad”) cholesterol remains elevated despite taking statins, the standard treatment for reducing the risk of heart attacks and other cardiovascular diseases. Lipfendra works by blocking the PCSK9 protein in the liver, allowing the body to remove more LDL cholesterol from the bloodstream. Existing PCSK9 therapies, offered as injections by several pharmaceutical companies, have been effective for years but have faced challenges related to high costs, insurance barriers, and limited patient access. Merck secured FDA approval after positive results from two clinical trials involving high-risk patients who received Lipfendra in addition to their regular cholesterol-lowering therapy. In one study involving around 3,000 participants, patients experienced a reduction of more than 55% in LDL cholesterol after six months. A second trial showed an average 59% decrease in LDL levels compared with those receiving a placebo. The cholesterol-lowering effect remained largely consistent over a year of treatment. Researchers reported that side effects, including dizziness and diarrhea, were generally mild and occurred at rates similar to those seen with the placebo. Patients are advised to take the medication on an empty stomach for optimal effectiveness. The FDA reviewed Lipfendra under its accelerated approval programme for promising therapies that address significant public health needs, enabling a faster regulatory process. Heart disease continues to be the leading cause of death in the United States, with elevated LDL cholesterol being a major contributor to heart attacks and strokes. While an LDL level below 100 mg/dL is generally considered healthy for most individuals, experts recommend reducing it to 70 mg/dL or lower for people with heart disease or those at high cardiovascular risk. The approval of Lipfendra offers a convenient oral alternative to injectable PCSK9 inhibitors and could significantly improve access to advanced cholesterol-lowering treatment for patients who require additional LDL reduction beyond statins. Source: AP

FDA Approves First-Ever Cholesterol-Lowering Pill Targeting PCSK9 for High-Risk Patients Read More »

US FDA Staff Expresses Concerns Over Merck’s Chronic Cough Drug Efficacy

Ahead of an upcoming meeting of independent experts, the U.S. health regulator’s staff has raised doubts about the adequacy of data supporting Merck’s chronic cough drug’s meaningful benefits, according to documents released on Wednesday. Merck’s shares dropped nearly 1 percent to $101.2 in afternoon trade following the news. This concern emerged after Merck submitted additional efficacy data for the drug, which the U.S. Food and Drug Administration (FDA) had previously rejected in January of the previous year. A panel of expert advisers to the FDA is scheduled to meet on Friday to assess the efficacy of Merck’s drug, gefapixant. The panel will specifically consider whether the data provided by Merck demonstrates that the reduction in cough frequency achieved with gefapixant is clinically significant for patients. Currently, there are no approved therapies for chronic cough in the United States. Globally, approximately 10 percent of the adult population is estimated to be affected by this condition, with about half of these individuals lacking an identifiable cause for their cough despite diagnostic tests. Gefapixant functions by blocking receptors that stimulate nerves, thereby suppressing the urge to cough. The drug underwent evaluation in two late-stage trials, where a higher dose demonstrated a statistically significant reduction in the average number of coughs per hour over a 24-hour period compared to a placebo. While the European Union and Japan have granted approval for Merck’s drug under the brand name Lyfnua, the FDA staff’s concerns highlight uncertainties about its efficacy in the U.S. market.

US FDA Staff Expresses Concerns Over Merck’s Chronic Cough Drug Efficacy Read More »